Introduction
Since the first successful transplantation of umbilical cord blood (UCB) was used to treat a patient with Fanconi anemia in 1988, 1 cord blood transplantation (CBT) has become an alternative to bone marrow transplantation in the treatment of a variety of diseases. Cord blood cells have many theoretical advantages as grafts for stem cell transplantation (SCT) because of their immaturity. As compared with those of adults, UCB stem cells produce larger in vitro hematopoietic colonies, and can be expanded in long-term culture in vitro. The properties of UCB cells should theoretically compensate for the relatively low numbers of cells contained in a single UCB unit, and through rapid expansion reconstitute myeloablated patients with fewer nucleated cells (by 1-2 logs) more so than the cells of bone marrow. However, low cell numbers compromise outcome if infused cell doses fall below critical limits. 2 To enhance engraftment, ex vivo expansion of UCB cells has been attempted in several studies with limited success. 3 However, recently, the transplantation of two partially human lymphocyte antigen (HLA)-matched UCB units has been attempted with promising engraftment result, 4 but this method is at the early development stage and little is known about the mechanism or kinetics of engraftment. Here, we analyzed early chimerism after transplants of two UCB units to clarify the early engraftment kinetics of this complex form of transplantation with multiple donors.
Patients and methods

Patient and cord blood unit selection
Eight patients diagnosed as having acute leukemia (five AML, two ALL) or severe aplastic anemia were given transplants of two UCB units consecutively at Seoul National University Children's Hospital. Patients were eligible for two units CBT when we were unable to secure a single 4-6/6 HLA-A, -B or DRB1 matched UCB unit with a nucleated cell dose of at least 3.5 Â 10 7 /kg. Written informed consent was obtained from all patients before transplantation.
Cord blood units were selected based on serologic typing for HLA-A and -B, low-resolution molecular typing for HLA-DRB1 loci and total nucleated cell dose. HLA-A, -B, -C, -DRB1 and -DQB1 loci were confirmed using a highresolution molecular method (polymerase chain reaction (PCR) single-strand conformation polymorphism).
Treatment
Patients received various conditioning regimens and graft-versus-host disease (GVHD) prophylaxis according to disease status (Table 1) . Patients 1 and 6 received total body irradiation (12 Gy), cytosine arabinoside (12 g/m Supportive care was performed according to the guidelines for SCT of our center. 5 Patients received ciprofloxacin, itraconazole, isoniazid and acyclovir as a prophylaxis for infection. Intravenous immunoglobulin (0.5 g/kg/dose) was infused weekly until day 100, and then monthly until day 180. Daily sulfamethoxazole/trimethoprim medication was discontinued 3 days before CBT and then restarted after white blood cell recovery. When fever exceeded 381C, broad-spectrum antibiotics were administered. Amphotericin B was given when fever persisted for more than 5 days despite an appropriate antibacterial treatment. CMV treatment with gancyclovir was started when CMV antigenemia was detected on routine weekly examination. Transfusions were given to maintain the hemoglobin level above 8 g/dl and the platelet count above 20 Â 10 9 /l. All blood products were irradiated with 20 Gy to avoid the risk of acute GVHD induction. Granulocyte colony-stimulating factor (300 mg/m 2 ) was administered from 1 day after CBT or from the last methotrexate infusion and then discontinued when the absolute neutrophil count (ANC) increased to more than 1.0 Â 10 9 /l for 3 consecutive days. Patients received low-molecular-weight heparin (nadroparine; fraxiparine, Sanofi-synthelabo, Paris, France) and/or lipo-PGE1 (eglandin; alprostadil, Welfide, Osaka, Japan) as a prophylaxis for veno-occlusive disease.
Assessment of engraftment and chimerism analysis
Myeloid engraftment was defined as the first of 3 consecutive days with an ANC of 0.5 Â 10 9 /l, and platelet recovery was defined to have occurred when the platelet count reached 20 Â 10 9 /l without transfusion. Hematopoietic chimerism of peripheral blood was evaluated by serial analysis of short tandem repeats from day 7, and when DNA could be obtained from blood samples. These analyses were performed at 3-4 days interval until ANC reached 1.0 Â 10 9 /l, and then weekly for 3 months after CBT.
The analytic method used was based on the quantitative amplification of informative polymorphic short tandem repeat (STR) regions in the recipient and donor using AmpFlSTR profiler PCR amplification kit (Applied Biosystems, Foster City, CA, USA) as per the manufacturer's instructions. Briefly, DNA from two donors and recipient were each amplified with fluorescence-conjugated PCR primers for representative alleles. Subsequently, fluorescent PCR products were separated on ABI PRISMR 310 Genetic Analyzer (Applied Biosystems), and GeneScan software (Applied Biosystems) was used to correlate allele peak areas to the percentage of donor or recipient DNA.
Results
Patient characteristics
Patients' (M:6; F:2) median age and body weight were 14 years (6-17 years) and 54.5 kg (23.0-62.9 kg), respectively. Patients 1-4 received CBT as a salvage treatment after the failure of previous transplants. Patient characteristics and transplantation results are summarized in Table 1 .
Engraftment and outcome
The median number of infused total nucleated cells, which was obtained by summing numbers in paired units before freezing was 4.68 Â 10 7 /kg (2.75-6.51 Â 10 7 /kg), and the median number of days required to reach an ANC of more than 0.5 Â 10 9 or 1.0 Â 10 9 /l were 19 days (14-32 days) and 22 days (16-34 days), respectively. Spontaneous platelet recovery to more than 20 Â 10 9 or 50 Â 10 9 /l required a median 33 days (24-112 days) and 43 days (24-123 days), respectively, excluding one patient (who died before recovery). CMV antigenemia occurred in six patients. Two patients progressed to CMV disease and one of them died owing to severe systemic CMV disease. Grade II acute GVHD occurred in four patients but resolved after treatment. Two patients relapsed 5 months after CBT.
Early engraftment kinetics
Early engraftment kinetics revealed a dominance of one of two administered units in each patient from the day of engraftment (40.5 Â 10 9 /l). The median values of the percentage of the dominant unit, non-dominant unit and recipient by chimerism analysis on the days of engraftment were 89.5% (60-100%), 0% (0-16%) and 5% (0-40%), respectively. All patients achieved complete donors chimerism (490%) at day 28. The median values of the percentage of the dominant unit, non-dominant unit and recipient at day 28 were 94.5% (80-100), 0% (0-12%) and 2.5% (0-8%), respectively ( Figure 1 ).
Characteristics of dominant and non-dominant units
The numbers of total nucleated cells, CD34 þ cells and CD3 þ cells infused, and the donor-recipient HLA disparities of the UCB units were viewed as factors that potentially influence dominancy. Units with a higher number of total nucleated cells and CD34 þ cells predominated in two and four of eight patients, respectively, and units with higher numbers of CD3 þ cells predominated in three of seven patients ( Table 2 ).
In terms of the degree of HLA mismatch in pairs of serotype of HLA-A, -B, and low-resolution genotype of HLA-DRB1, the better HLA-matched unit predominated in five of eight patients. In another two with the same HLA mismatch of six serotype and low-resolution genotype, units better matching high-resolution genotypes HLA-A, -B, -C, -DRB1 and -DQB1 predominated ( Table 2) .
Discussion
Two units CBT is a promising method with a better engraftment potential, 4 and was recently proposed to have a better graft-versus-leukemia effect, and thus to offer a better chance of survival than single unit CBT. 6 However, the mechanisms underlying this advantage and the kinetics of this engraftment are not understood.
Our preliminary results showed the dominance of one unit in all transplants, which concurs with a previous report by the Minnesota group, 4 although mixed chimerism occurred in the first case at about 3 months after CBT during CMV treatment with gancyclovir. It has also been reported that mixed chimerism may be maintained for as long as 100 days after two units CBT. 7 The most dramatic result of the present study was that dominancy was found to occur early after transplantation. However, the exact time for determining dominancy has not been determined, and it may even occur just after the infusion of the two units.
It is not known why one unit dominates over the other. Barker et al. 4 reported that a larger CD3 þ cells dose is associated with dominance, but with some exceptions, and it is possible that the unit with the larger number of CD3 þ cells might defeat the weaker unit. However, in present study, less than half of the cases analyzed showed dominance of the unit with more CD3 þ cells. Nevertheless, the present study suggests that the degree of HLA mismatch is also important.
Multiple factors associated with outcomes of CBT could influence the determination of dominance, such as those factors that affect the recipient environment (underlying disease, previous treatment, conditioning regimen, use of antithymocyte globulin/antilymphocyte globulin, and the method of GVHD prophylaxis), the characteristics of each UCB unit and HLA disparity. 8 For this reason, the selection of the two units requires consideration of the above factors. However, optimal selection guidelines that take into account influencing factors are unavailable. The selection of one strong unit (with high numbers of total nucleated and/or CD3 þ cells) and one weak unit to activate the strong one, and thus create dominance of one unit, might result in a better outcome than the currently favored combination of two strong units, which presents the possibility of persistent mixed chimerism.
In conclusion, two units CBT produced promising results, and the determination of dominancy was found to be an early event influenced by multiple factors. Table 2 Characteristics of dominant and non-dominant cord blood units 
